Circulating levels of soluble apoptosis-related molecules in patients with multiple sclerosis

Abstract Evidence exists that apoptotic elimination of autoreactive T lymphocytes is defective in multiple sclerosis (MS). Here, we measured serum levels of soluble forms of Fas (sFas), Fas ligand (sFasL) and TNF-related apoptosis-inducing ligand (sTRAIL) in 38 healthy controls (HC) and 92 untreated...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuroimmunology 2013-10, Vol.263 (1), p.152-154
Main Authors: Moreno, Montserrat, Sáenz-Cuesta, Matías, Castilló, Joaquín, Cantó, Ester, Negrotto, Laura, Vidal-Jordana, Angela, Montalban, Xavier, Comabella, Manuel
Format: Article
Language:English
Subjects:
Adult
Allergy and Immunology
Apoptosis
Apoptosis - immunology
Apoptosis Regulatory Proteins - blood
Apoptosis Regulatory Proteins - physiology
Biomarkers - blood
Down-Regulation - immunology
Fas
Fas Ligand Protein - blood
fas Receptor - blood
FasL
Female
Humans
Male
Middle Aged
Multiple sclerosis
Multiple Sclerosis - immunology
Multiple Sclerosis - metabolism
Multiple Sclerosis - pathology
Neurology
Relapse
Solubility
TNF-Related Apoptosis-Inducing Ligand - blood
TRAIL
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Evidence exists that apoptotic elimination of autoreactive T lymphocytes is defective in multiple sclerosis (MS). Here, we measured serum levels of soluble forms of Fas (sFas), Fas ligand (sFasL) and TNF-related apoptosis-inducing ligand (sTRAIL) in 38 healthy controls (HC) and 92 untreated MS patients with different clinical forms and activity phases of the disease by immunoassay. Serum levels of sFas, sFasL and sTRAIL did not differ between MS patients and HC. sTRAIL levels were significantly decreased in RRMS during relapses. These findings support a role of TRAIL in the pathogenesis of MS, especially during the acute phases of the disease.
ISSN:0165-5728
1872-8421
DOI:10.1016/j.jneuroim.2013.07.013